(Q38364912)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

review article

1 reference

title

A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Umberto Vitolo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

T E Witzig

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

G S Nowakowski

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

T M Habermann

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

A Goy

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

F J Hernandez-Ilizaliturri

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

N Fowler

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

M S Czuczman

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

publication date

23 February 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

1667-1677

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712458%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Treatment of older patients with mantle-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Lenalidomide and thalidomide: mechanisms of action--similarities and differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Combination of low doses of enzastaurin and lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV102

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDV102

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712458%20AND%20SRC:MED&resulttype=core&format=json

release_lggqp63n3bfg3n7a6zs4byq6u4

1 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lggqp63n3bfg3n7a6zs4byq6u4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712458%20AND%20SRC:MED&resulttype=core&format=json